KDR and non-small cell lung carcinoma: Nevertheless, the meta-analysis included high-quality RCTs without indication of publication bias, providing compelling evidence for the safety and efficacy of EGFR-TKIs plus anti-VEGFR combination therapy in advanced NSCLC patients.